

# ForPatients

by Roche

Neovascular Age-related Macular Degeneration

## A Study Of The Efficacy, Safety, And Pharmacokinetics Of The Port Delivery System With Ranibizumab In Chinese Patients With Neovascular Age-Related Macular Degeneration

**Trial Status**  
Recruiting

**Trial Runs In**  
1 Countries

**Trial Identifier**  
NCT05562947 YR42983

---

The source of the below information is the publicly available website [ClinicalTrials.gov](https://clinicaltrials.gov). It has been summarised and edited into simpler language.

### *Trial Summary:*

This study will evaluate the efficacy, safety, and pharmacokinetics of ranibizumab 100 mg/mL delivered Q24W via the PDS implant compared with ranibizumab 0.5 mg delivered as a Q4W intravitreal injection in Chinese patients with nAMD.

**Hoffmann-La Roche**  
Sponsor

**Phase 3**  
Phase

---

**NCT05562947 YR42983**  
Trial Identifiers

---

### *Eligibility Criteria:*

**Gender**  
All

**Age**  
>=50 Years & <= 80 Years

**Healthy Volunteers**  
No

---